Evidence map›Paper›PMID 38765881›Full record

ArticleJournal of addiction psychiatry2024

Summary Document Research on RDS Anti-addiction Modeling: Annotated Bibliography.

Kenneth Blum, David Baron, Thomas McLaughlin, Panayotis K Thanos, Catherine Dennen, Mauro Ceccanti, Eric R Braverman, Alireza Sharafshah, Kai-Uwe Lewandrowski, John Giordano and 1 more

Abstract readBibliography
In one paragraph

Article in Journal of addiction psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. How to Combat the Global Opioid Crisis.CPQ neurology and psychology · 2023
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kenneth BlumCenter for Sports and Mental Health, Western University Health Sciences, Pomona, CA, USA.
David BaronCenter for Sports and Mental Health, Western University Health Sciences, Pomona, CA, USA.
Thomas McLaughlinThe Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA.
Panayotis K ThanosBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, State University of New York, Buffalo, NY, USA.
Catherine DennenDepartment of Family Medicine, Jefferson University School of Medicine, Philadelphia, PA, USA.
Mauro CeccantiDepartment of Translational and Precision Medicine, Sapienza University, Rome, Italy.
Eric R BravermanThe Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA.
Alireza SharafshahDivision of Genetics, Department of Cell and Molecular Biology and Microbiology, School of Science and Biotechnology, University of Isfahan, Isfahan, Iran.
Kai-Uwe LewandrowskiDepartment of Orthopaedics, Fundación Universitaria Sanitas Bogotá D.C. Colombia.
John GiordanoThe Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA.
Rajendra D BadgaiyanThe Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA.

Funding

Dopamine Neurotransmission in Tourette SyndromeR01NS073884 · NINDS · UNIVERSITY OF MINNESOTA · PI BADGAIYAN, RAJENDRA D · 2012 to 2016
$2.2M
A Systematic Medical Approach to Reward Transformation (SMART) for Brain Health in Opioid Use DisorderR41MD012318 · NIMHD · VERSA INTEGRATED SOLUTIONS, INC. · PI BLUM, KENNETH, GONDRE-LEWIS, MARJORIE C · 2017 to 2017
$221k
Dopamine Neurotransmission in AddictionI01CX000479 · VA · VA WESTERN NEW YORK HEALTHCARE SYSTEM · PI BADGAIYAN, RAJENDRA D · 2013 to 2014
–
CSRD VA I01 CX000479NIMHD NIH HHS R41 MD012318NINDS NIH HHS R01 NS073884
6 · The paper itself

Abstract

Annotated bibliography of genetic addiction risk severity (GARS) publications, pro-dopamine regulation in nutraceuticals (KB220 nutraceutical variants), and policy documents. Further research is required to encourage the field to consider "Reward Deficiency Syndrome (RDS) Anti-addiction Modeling" which involves early risk identification by means of genetic assessment similar to GARS, followed by induction of dopamine homeostasis by means of genetically guided pro-dopamine regulation similar to KB220. These results suggest that genetically based treatments may be a missing piece in the treatment of substance use disorder (SUD).

Indexed as

Anti-addiction modelingGenetic addiction risk severitySubstance use disorder

Identifiers

PMID38765881
PMCPMC11100022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.